Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a phase II clinical study of Cadonilimab (AK104) combined with or without
chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung
cancer
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Zunyi Medical University
Collaborators:
Guizhou Provincial People's Hospital Guizhou Tongren People's Hospital The First People's Hospital of Zunyi The People"s Hospital of Xingyi The Second Affiliated Hospital of Guizhou Medical University